Clovis Oncology, Inc.
CLVSQ
OTC PK
| 09/30/2022 | 06/30/2022 | ||||
|---|---|---|---|---|---|
| Revenue | -4.60% | -6.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.60% | -6.14% | |||
| Cost of Revenue | -7.71% | -2.45% | |||
| Gross Profit | -3.60% | -7.28% | |||
| SG&A Expenses | -6.78% | 11.56% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -61.46% | 256.38% | |||
| Total Operating Expenses | -18.17% | 8.18% | |||
| Operating Income | 25.51% | -17.92% | |||
| Income Before Tax | 21.57% | -18.38% | |||
| Income Tax Expenses | 185.37% | 65.83% | |||
| Earnings from Continuing Operations | 21.47% | -18.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 21.47% | -18.55% | |||
| EBIT | 25.51% | -17.92% | |||
| EBITDA | 26.32% | -18.67% | |||
| EPS Basic | 21.79% | -13.73% | |||
| Normalized Basic EPS | 21.89% | -13.61% | |||
| EPS Diluted | 21.79% | -13.73% | |||
| Normalized Diluted EPS | 21.89% | -13.61% | |||
| Average Basic Shares Outstanding | 0.41% | 4.22% | |||
| Average Diluted Shares Outstanding | 0.41% | 4.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
